Roche Holding AG scores 100 for management and 21 for moat. The management score rests on a return on invested capital of 19.6% and a gross margin of 73.7% — figures that describe a business turning capital into profit efficiently. Debt sits at 0.98x equity. A narrow moat alongside exceptional management is a combination worth understanding before the price matters at all.
Three independent anchors set the price worth paying. Growth is modelled at 1.7% a year, below the 2.0% actually measured over the last decade — the model caps growth rather than extrapolating a good run forwards. The exit multiple assumed is 8.0x. That produces an intrinsic value of $7.96, a 10-CAP price of $60.27 and a payback time price of $51.98, with the value zone set at the highest of the three, $60.27. Today's price of $52.31 sits inside that zone.
The price sits inside the value zone, but the business scores 21 for moat and 100 for management. Cheap and good are different tests, and only one of them is passed here.
| Price | $52.31 |
| Market cap | $333.5B |
| P/E ratio | 15.3x |
| Return on invested capital | 19.6% |
| Gross margin | 73.7% |
| Debt to equity | 0.98x |
| Free cash flow yield | 5.1% |
| Growth rate used | 1.7% |
| Growth rate measured | 2.0% |
| Exit multiple assumed | 8.0x |
| Company | Moat | Buy price |
| Merck & Co. Inc. (MRK) | 56 | $85.17 |
| Astrazeneca Plc (AZN) | 95 | $103.83 |
| Amgen (AMGN) | 41 | $225.75 |
| AbbVie Inc. (ABBV) | 22 | $114.59 |
Every number above is built on assumptions that can be changed. In Moatly you can move the growth rate, the exit multiple and the margin of safety and watch every figure recalculate, so you are testing your own view of Roche Holding AG rather than accepting ours.